Are there any activitites for this which has a potential for upside for pran in nasdaq
BIG DEAL TO ACQUIRE UP TO 9 MARKETED PRODUCTS IMMINENT = 20+ BAGGER POTENTIAL !!! AQSZF (MC $11 M) is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $11 Million ,this unknown stock is definitely one of the cheapest Biotech in the sector .Stock should be at minimum $2+ right now .
Market Cap :US$ 11 Million Cash $4.1 Million << enough untill mid 2018 Price 0.18
File for CDN approval of Oxcarbazepine XR in 1H 2017
Additional Product Deals in 2017
Partnership for AQS1301 in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018
why such a low volume and such a big difference in bid and ask
I am not sure why some investors stick with Prana. Maybe they are afraid to admit defeat (it was not easy for me); maybe making a loss official is too painful. In any event, I believe that there are many stocks with more promise than Prana has and that are moving forward so that rewards may actually be realized in THIS lifetime. Prana has played it close to the vest for too long. It is not my way to be negative toward another's dream, but I do not see good faith here. My recommendation is that investors look to a company that is better managed, is more straightforward with, and fair to investors, and is progressing normally. There are many such opportunities in biotech and elsewhere.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.1 In other words, the correlation coefficient of the other stoc
I don't care how many degrees all of PRAN's associates have between them, or how many dozens of articles they've published over the past 20 years. As a publicly traded company, they are terrible. The stock is a loser.
Posts about PBT434 on The Science of Parkinson's disease
Posts about PBT434 written by Simon
For those interested, Prana have offices in the same street as The Florey Institute of Neuroscience and Mental Health. Prana co founder Colin Masters co heads the Neurodegeneration Division. heads the AIBL study,and several labs. Other labs whith ties to Prana are: Paul Adlard (Synaptic Neurobiology Laboratory) Kevin Barnham (Neurotherapeutics Laboratory) Ashley Bush (Oxidation Biology Laboratory)[co-founder] Robert Cherny (Prana Laboratory) David Finkelstein (Pre-clinical Parkinson's Disease Research Laboratory) Colin Masters (Neuropathology and Neurodegeneration Laboratory and The Australian Imaging Biomarker and Lifestyle Study) If you go to the Florey site you can see all of these labs are doing work for Prana. The Florey is probably the biggest neuro research institute in the southern hemisphere. When you add Rudy Tanzi at Harvard, the other Prana co-founder, Prana have access to an enormous amount of research. muscle for a company of it's size. [Rudolph Tanzi, PhD, is the vice chair of the Department of Neurology and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital, and serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.]
To repeat my earlier themes: 1) Does anyone know how the employees of Prana (I think there are nine) spend their work days? 2) Has anyone noticed a pattern with regard to stock price related to inflated excitement, then selling after the sucker - er, I mean - investors have jumped on the bandwagon? Seems there are people who seek out a molecule that will help them tell an apparently compelling story, then exploit the heck out of it. Very profitable (albeit parasitic) careers have been made in this way.
Anyone know why this is up like this on no news that I can see?
Prana's lab is at the Florey Institute of Neuroscience and Mental Health. It is the biggest brain research institute in the southern hemisphere. https://www.florey.edu.au/ The Florey is at 30 Royal Parade Parkville and Prana's office is at 369 in the same street. Prana's lab: https://www.florey.edu.au/node/4120 Prana co-founder Ashley Bush runs the Oxidation Biology Lab at the Florey PBT2 co-inventor Kevin Barnham runs the Neurotherapeutics Lab The Preclinical Parkinson's Disease Research Lab is run by David Finkelstein The Synaptic Neurobiology Lab is run by Paul Adlard. If you look through the site, all these labs feature work with Prana. Then there is Colin Masters, the other co-founder at the Florey He is Head of the AIBL study. Co-head of the Neurodegeneration Division Head of the Neuropathology and Neurodegeneration Lab Co-head of the National Dementia Diagnostics Lab When you also take into consideration they also have work done at co-founder Rudy Tanzi's lab at Harvard, they probably have more research muscle available than many much bigger companies.
The Florey - Institute of Neuroscience and Mental Health
Last week Friday we had 3.7M shares traded, without news. That is over 40% of all Prana's shares, for sure there was also a lot of short selling. May be this down turn will take for a while.
why this thing moving like this
This PRAN stock could become the next AKTX from $6 to $20+ in only 2 weeks
Very difficult to see PRAN not making a big run north. if you guys have questions you should ask awesomeSTO-CKS. They often respond to my emails which is helpful.